ACHN - BioCryst Pharmaceuticals: BCX7353 Phase 3 Results To Make Or Break This Story

BioCryst Pharmaceuticals (BCRX) caught my eye recently because of the company advancing an oral factor D inhibitor into the clinic – BCX9930. Complement inhibition is an area of interest for me and I’ve recently written an article on Achillion Pharmaceuticals (ACHN) which is currently ahead of BioCryst’s BCX9930. However, BCX7353 is BioCryst’s main asset right now and the company is about to report phase 3 results in hereditary angioedema (prophylaxis) this quarter. I’ve done a good amount of research on BCX7353 and have decided to write this article, but without taking